Ophthalmic Preparations: Formulation Considerations
This webinar is part one of three in the webinar series on ophthalmic preparations. Part I, Principles of Ocular Pharmacology, reviews the basic principles of ocular pharmacology, including anatomy and pharmacokinetics. Part II, Formulation Considerations, surveys the art and science of compounding by reviewing the guidelines for sterile compounding and for preparing ophthalmic formulations. Finally, Part III, Compounding Opportunities, applies what was learned by looking at specific examples of compounding opportunities in both human and veterinary ophthalmology.
Ophthalmic diseases can be treated either with pharmacotherapy, surgery, or a combination of both. We are fortunate to have many of the ophthalmic drugs we need manufactured and readily accessible with a prescription. Sometimes, however, what an ophthalmologist needs to effectively treat a patient differs from what is available in the market. Compounding exists to bridge this gap in the delivery of healthcare. In this webinar, the second in the series Ophthalmic Preparations, we review the main indications for compounding.
Due to the sensitivity of the eye to biological insults and due to its proximity to the brain, compounded ophthalmic preparations must be prepared in a sterile environment. Requirements for sterility will be discussed by reviewing important elements found in United States Pharmacopoeia (USP) General Chapter <797> Pharmaceutical Compounding – Sterile Preparations. Finally, based on USP General Chapter <771> Ophthalmic Products – Quality Tests, we take a closer look at what makes an ophthalmic formulation; its constituent ingredients, its ideal physicochemical properties, and quality control parameters that must be met before the drug is dispensed.
- Pharmacy Technicians
- Nurse Practitioners
- Review the challenges in ocular drug delivery and the indications for compounding.
- Discuss the regulations governing sterile compounding, with reference to the USP General Chapter <797>.
- Learn and understand the purpose of the chemical constituents of an ophthalmic compounded sterile preparation (CSP), including the active pharmaceutical ingredient (API) and the different excipients.
- Identify the ideal physicochemical properties of an ophthalmic CSP, which must be achieved to ensure drug efficacy and patient safety, comfort and compliance.
- Recognize the importance of the quality control parameters that must be met prior to drug dispensing.
The webinar is copyright © 2018 LP3 Network.
High speed internet connectivity and an updated internet browser is required to attend the webinar. The broadband recommended is 1 Mbps or better. The minimum browser requirements to attend the webinar are:
- Google Chrome v39 or later
- Mozilla Firefox v34 or later
- Internet Explorer v8 or later
- Microsoft Edge
- Apple Safari v6 or later
JADE MARIE LASISTE, MD, MSc
Jade Marie Lasiste completed her Masters of Science in Pathology, alongside a research fellowship in Ocular Pathology, at McGill University. Her work was focused on cataracts and uveal melanoma, for which she was the recipient and several national and international research awards. In addition she completed her Bachelor of Science in Molecular Biology and Biotechnology and her Doctor of Medicine at the University of the Philippines. She is currently a Junior Medical Writer at LP3 Network Inc.